Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PPID | Q08752 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL473103 | 0.81 | TDP1 (0.55) | LMNACYP1A2ALDH1A1CYP2C19CYP3A4 | |
| SCHEMBL7434407 | 0.80 | GAA (0.60) | LMNACYP1A2PTGS2ALDH1A1CYP2C19 | |
| SCHEMBL7396978 | 0.79 | CA12 (0.57) | LMNAALDH1A1SMN1; SMN2L3MBTL1NPC1 | |
| SCHEMBL474570 | 0.78 | SMN1; SMN2 (0.53) | LMNACYP1A2ALDH1A1CYP2C19CYP3A4 | |
| SCHEMBL16762137 | 0.74 | LMNA (0.55) | LMNAALDH1A1SMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL10460258 | 0.73 | CTSL (0.52) | ALDH1A1L3MBTL1ATM | |
| SCHEMBL9937386 | 0.73 | SMN1; SMN2 (0.47) | LMNACYP1A2ALDH1A1CYP2C19CYP3A4 | |
| SCHEMBL4883409 | 0.73 | BRD4 (0.61) | L3MBTL1NPC1RAB9A | |
| SCHEMBL3463370 | 0.73 | CASP1 (0.52) | ALDH1A1CYP3A4SMN1; SMN2MAPT | |
| SCHEMBL25771684 | 0.72 | ALDH1A1 (0.59) | ALDH1A1MAPTL3MBTL1ATMNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697348-B1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 2011-12-28 | — | — | EP | disclosed |
| US-7696226-B2 | HIV protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2010-04-13 | — | — | US | disclosed |
| EP-1697348-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050159469-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2005-07-21 | — | — | US | disclosed |
| WO-2005061487-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159469-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | LMNA 3100/4885CYP1A2 2459/4885PTGS2 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.